Novo Nordisk Receives the US FDA’s Refusal to File Letter for Semaglutide to Treat T2D

Novo Nordisk Receives the US FDA's Refusal to File Letter for Semaglutide to Treat T2D

Novo Nordisk Receives the US FDA’s Refusal to File Letter for Semaglutide to Treat T2D

Parag Narang

Parag Narang is a Digital Marketing Associate at PharmaShots, a division of Octavus Consulting. He manages the digital marketing as well as the designing ideas for PharmaShots. He has a degree in Bachelor of Business Administration along with Post Graduate Program in Management (Marketing). Parag manages all the social media handles very well since he has a good experience in Marketing & Sales.

Related post